Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EA NASDAQ:INCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEAElectronic Arts$206.350.0%$202.84$146.97▼$206.82$51.76B0.641.91 million shs1.38 million shsINCYIncyte$114.23-2.1%$103.58$67.17▼$118.97$23.32B0.761.86 million shs1.48 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEAElectronic Arts-0.03%+0.56%+1.52%+1.73%+38.78%INCYIncyte-2.12%-1.20%+5.25%+16.93%+66.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEAElectronic Arts$206.350.0%$202.84$146.97▼$206.82$51.76B0.641.91 million shs1.38 million shsINCYIncyte$114.23-2.1%$103.58$67.17▼$118.97$23.32B0.761.86 million shs1.48 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEAElectronic Arts-0.03%+0.56%+1.52%+1.73%+38.78%INCYIncyte-2.12%-1.20%+5.25%+16.93%+66.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEAElectronic Arts 2.05Hold$196.64-4.70% DownsideINCYIncyte 2.36Hold$109.10-4.49% DownsideCurrent Analyst Ratings BreakdownLatest INCY and EA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026INCYIncyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/14/2026INCYIncyte BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$117.00 ➝ $134.007/13/2026INCYIncyte BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$94.00 ➝ $112.007/7/2026INCYIncyte Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$95.00 ➝ $99.006/29/2026INCYIncyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)6/26/2026INCYIncyte UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$103.00 ➝ $113.006/24/2026INCYIncyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$140.006/22/2026INCYIncyte BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Market Perform$75.00 ➝ $94.006/22/2026INCYIncyte Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$103.00 ➝ $105.006/15/2026INCYIncyte BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform5/28/2026EAElectronic Arts ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEAElectronic Arts$7.53B6.87$7.07 per share29.19$27.03 per share7.63INCYIncyte$5.14B4.44$6.05 per share18.88$26.32 per share4.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEAElectronic Arts$887M$3.4959.1327.512.3111.78%23.41%11.71%8/4/2026 (Estimated)INCYIncyte$1.29B$7.0816.1314.681.0726.71%26.66%19.77%7/28/2026 (Estimated)Latest INCY and EA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q1 2027EAElectronic Arts$0.78N/AN/AN/A$1.48 billionN/A7/28/2026Q2 2026INCYIncyte$1.97N/AN/AN/A$1.43 billionN/A4/28/2026Q1 2026INCYIncyte$1.38$1.81+$0.43$1.47$1.22 billion$1.27 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEAElectronic Arts$0.760.37%+17.45%21.78%N/AINCYIncyteN/AN/AN/AN/AN/ALatest INCY and EA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/1/2026EAElectronic Artsquarterly$0.190.38%5/27/20265/27/20266/17/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEAElectronic Arts0.221.051.05INCYIncyte0.013.683.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEAElectronic Arts90.23%INCYIncyte96.97%Insider OwnershipCompanyInsider OwnershipEAElectronic Arts0.24%INCYIncyte16.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEAElectronic Arts14,600250.75 million250.15 millionOptionableINCYIncyte2,844199.78 million167.42 millionOptionableINCY and EA HeadlinesRecent News About These CompaniesIncyte: VGA039 Data Reinforces Diversification Strategy as Analyst Reiterates Hold and Keeps $103 Price Target Unchanged2 hours ago | tipranks.comIncyte Corporation $INCY Shares Purchased by J. Safra Sarasin Holding AG3 hours ago | marketbeat.comProcyon Advisors LLC Buys 20,117 Shares of Incyte Corporation $INCY3 hours ago | marketbeat.comIncyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3July 13 at 9:08 PM | finance.yahoo.comUnpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology StocksJuly 13 at 11:07 AM | finance.yahoo.comIncyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood DisorderJuly 13 at 9:51 AM | benzinga.comIncyte (NASDAQ:INCY) Price Target Raised to $112.00July 13 at 9:11 AM | marketbeat.comIncyte Corporation $INCY Shares Sold by Teachers Retirement System of The State of KentuckyJuly 13 at 5:51 AM | marketbeat.comSumitomo Mitsui Trust Group Inc. Has $39.76 Million Holdings in Incyte Corporation $INCYJuly 13 at 5:03 AM | marketbeat.comIncyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease TypesJuly 13 at 4:00 AM | businesswire.comIncyte Corporation $INCY Position Boosted by Arbejdsmarkedets TillaegspensionJuly 13 at 3:13 AM | marketbeat.comIncyte Corporation $INCY Shares Sold by Applied Finance Capital Management LLCJuly 13 at 3:12 AM | marketbeat.comCandriam S.C.A. Reduces Stock Position in Incyte Corporation $INCYJuly 12 at 10:40 AM | marketbeat.comIncyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 ProgramsJuly 10, 2026 | businesswire.comUK MHRA approves Incyte Biosciences’ retifanlimab to treat advanced Merkel cell skin cancerJuly 8, 2026 | pharmabiz.comPIncyte Acquires Vega Therapeutics, Expands Hematology PipelineJuly 8, 2026 | theglobeandmail.com2 Fast-Growing Pharmaceutical Stocks to Buy NowJuly 8, 2026 | fool.comIncyte to Report Second Quarter Financial ResultsJuly 8, 2026 | finance.yahoo.comIncyte completes acquisition of Vega Therapeutics, a wholly owned subsidiary of Star TherapeuticsJuly 8, 2026 | pharmabiz.comPBurney Co. Boosts Stock Holdings in Incyte Corporation $INCYJuly 7, 2026 | marketbeat.comIncyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology PortfolioJuly 6, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINCY and EA Company DescriptionsElectronic Arts NASDAQ:EA$206.35 -0.06 (-0.03%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$206.52 +0.17 (+0.08%) As of 09:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Electronic Arts Inc. develops, markets, publishes, and distributes games, content, and services for game consoles, PCs, mobile phones, and tablets worldwide. It develops and publishes games and services across various genres, such as sports, racing, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Need for Speed, and license games from others, including FIFA, Madden NFL, UFC, and Star Wars brands. The company licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution and retail channels, as well as directly to mass market retailers, specialty stores, and distribution arrangements. Electronic Arts Inc. was incorporated in 1982 and is headquartered in Redwood City, California.Incyte NASDAQ:INCY$114.23 -2.48 (-2.12%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$113.78 -0.45 (-0.40%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Baggage Claim: Apollo’s $7.7 Billion Bid to Acquire easyJet The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain Fission for Profits: Unlocking America’s Uranium Vault The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
